DARPA’s latest program looking for a new PPE type made for soldiers

0
Share

The term ‘PPE’ is something we are all familiar with because the important role of this protective equipment has been played during a pandemic. However, there is a downside to this private equipment, usually – usually large, uncomfortable, and slows down your ability to work. That’s why Darpa announced a new project that tried to revolution PPE for the battlefield with the development of ‘ppb.’

PPB DARPA stands for personalized protective biosystem, a new program that has peeled many companies to develop technology that can reduce how much PPE is needed when faced with biological and chemical threats. In explaining the purpose of this program, the Darpa PPB program manager Eric Van Gieson said:

PPB aims to overcome the limitations of PPE, including the vulnerability of threats-specific, thermal load / logistics, and the risk of potential exposure. The ability to provide CB protection that is not intended will be very valuable in maximizing the right time of the target, providing operational flexibility, extending the duration of the mission, and allowing operations in a harsh environment, regardless of threats.

The DARPA PPB program will run for five years and will consist of two different ‘technical fields,’ which will try to keep the body from contact with external threats when offering a 100 percent survival rate for 10+ unexplained chemicals and biological. threat.

The second technical area will focus on neutralizing the threat of CB of things such as eyes, skin, and mouth, and other vulnerable internal network barriers. ‘This system will be in a certain way to be configured, according to DARPA, although it does not enter specifically about what is in his mind.

DARPA has given a PPB contract to Charles River Analytics, Flir Systems, and Leidos for the development of this technology. This program will work with the FDA on the rules of things, note that it will look for new drug approval investigations at the end of the PPB program.